sk&f 83959 has been researched along with pentazocine in 1 studies
| Studies (sk&f 83959) | Trials (sk&f 83959) | Recent Studies (post-2010) (sk&f 83959) | Studies (pentazocine) | Trials (pentazocine) | Recent Studies (post-2010) (pentazocine) |
|---|---|---|---|---|---|
| 94 | 0 | 46 | 2,262 | 353 | 138 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L; Jin, G; Wang, G; Zhang, A; Zhao, B; Zhao, J; Zhen, X | 1 |
1 other study(ies) available for sk&f 83959 and pentazocine
| Article | Year |
|---|---|
SKF83959 is a potent allosteric modulator of sigma-1 receptor.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Allosteric Regulation; Animals; Brain; Cell Line; Drug Synergism; HEK293 Cells; Humans; Liver; Male; Pentazocine; Progesterone; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, sigma; Sigma-1 Receptor | 2013 |